Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 82.5%

Neg 0% Neu 82.5% Pos 0%

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.